SK bioscience Co.,Ltd. (302440.KS)
KRW 54700.0
(-5.36%)
KRW 54700.0
(-5.36%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 20.57 Billion KRW | -81.85% |
| 2022 | 113.33 Billion KRW | 6.68% |
| 2021 | 106.23 Billion KRW | -12.9% |
| 2020 | 121.96 Billion KRW | -2.48% |
| 2019 | 125.07 Billion KRW | -9.34% |
| 2018 | 137.96 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 99.48 Billion KRW | -1.31% |
| 2024 Q1 | 100.8 Billion KRW | 389.95% |
| 2023 Q1 | 67.96 Billion KRW | -40.03% |
| 2023 FY | 20.57 Billion KRW | -81.85% |
| 2023 Q4 | 20.57 Billion KRW | -12.65% |
| 2023 Q3 | 23.55 Billion KRW | -10.87% |
| 2023 Q2 | 26.42 Billion KRW | -61.12% |
| 2022 Q3 | 127.45 Billion KRW | -23.69% |
| 2022 Q2 | 167.01 Billion KRW | 44.78% |
| 2022 Q1 | 115.35 Billion KRW | 8.58% |
| 2022 FY | 113.33 Billion KRW | 6.68% |
| 2022 Q4 | 113.33 Billion KRW | -11.07% |
| 2021 Q4 | 106.23 Billion KRW | -0.43% |
| 2021 Q2 | 102.35 Billion KRW | 0.09% |
| 2021 Q3 | 106.69 Billion KRW | 4.24% |
| 2021 FY | 106.23 Billion KRW | -12.9% |
| 2021 Q1 | 102.25 Billion KRW | -16.16% |
| 2020 Q2 | 126.82 Billion KRW | -1.09% |
| 2020 FY | 121.96 Billion KRW | -2.48% |
| 2020 Q4 | 121.96 Billion KRW | -2.6% |
| 2020 Q3 | 125.22 Billion KRW | -1.26% |
| 2020 Q1 | 128.21 Billion KRW | 2.52% |
| 2019 Q2 | 140.82 Billion KRW | -1.44% |
| 2019 FY | 125.07 Billion KRW | -9.34% |
| 2019 Q3 | 140.11 Billion KRW | -0.5% |
| 2019 Q4 | 125.07 Billion KRW | -10.74% |
| 2019 Q1 | 142.87 Billion KRW | 3.56% |
| 2018 Q4 | 137.96 Billion KRW | -3.37% |
| 2018 Q3 | 142.77 Billion KRW | 0.0% |
| 2018 FY | 137.96 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | 3.03 Billion KRW | -576.825% |
| Green Cross Holdings Corporation | 1280.16 Billion KRW | 98.393% |
| Green Cross Holdings Corporation | 724.02 Billion KRW | 97.158% |
| Pharmicell Co., Ltd. | 3.02 Billion KRW | -579.502% |
| Green Cross Corporation | 724.02 Billion KRW | 97.158% |
| GeneOne Life Science, Inc. | 17.15 Billion KRW | -19.895% |
| Celltrion, Inc. | 1890.42 Billion KRW | 98.912% |
| Samsung Biologics Co.,Ltd. | 1909.33 Billion KRW | 98.922% |
| SK Biopharmaceuticals Co., Ltd. | 178.05 Billion KRW | 88.445% |
| Prestige BioPharma Limited | 89.66 Billion KRW | 77.056% |